MedImmune Cambridge
www.cambridgeantibody.comCambridge Antibody Technology (CAT), known as MedImmune as of 29 October 2007, is committed to advancing science to develop better medicines that help people live healthier, longer and more satisfying lives.
In June 2006, AstraZeneca (AZ) acquired CAT, and then acquired MedImmune, Inc. in June 2007. These acquisitions by AstraZeneca represent a major long-term strategic investment in novel biological therapeutics, expanding and diversifying AZ’s R&D science base to address drug targets through three technological approaches: small molecules, biologics and vaccines.
CAT’s leading discovery platform and early development experience is fully complementary to MedImmune’s discovery and more mature development and state-of-the-art manufacturing facilities.
MedImmune Cambridge currently employs around 310 people.
Staff
 Patrick Round MBBS FRCA FFPM, Senior Vice President DevelopmentPatrick Round joined CAT in 2004 as VP Development and is responsible for all CAT\'s product development activities. Before joining CAT, he was Director of Development at Celltech Group plc (now part of UCB) and was responsible for development activities in pre-clinical, clinical, regulatory, biometrics, project management, pharmacovigilance and quality assurance. He has also held positions at GlaxoWellcome and Novo Nordisk. He is a qualified anaesthetist and graduated in Medicine from Charing Cross Hospital Medical School, London. |  Lynn Lester MBA, Senior Vice President Human ResourcesLynn Lester joined CAT in 2000 and was appointed VP Human Resources in December 2004. Lynn previously worked as an independent consultant in performance management and HR strategies and has also worked as a senior management consultant for QUALTRAK Ltd, an agency specialising in performance management, and as a lecturer in business and management. Lynn has a Certificate in Education from the University of Leeds and an MBA and Diploma in Management, both from the Open Business School. |
 Alex Duncan MA PhD, Senior Vice President DiscoveryAlex Duncan joined CAT in 1994. Prior to his appointment as Senior Vice President Drug Discovery Alex held the position of Head of Antibody Engineering. Before joining CAT, he was a Research Fellow at the University of California and prior to that, a Lucille P Markey Visiting Fellow also at the University of California. Alex is a Medical Research Council (MRC) graduate from the Laboratory of Molecular Biology in Cambridge. |  Dr Hamish Cameron, Chief Executive and DirectorDr Cameron, a physician by training, joined CAT following a number of senior R&D appointments in AstraZeneca, including Head of the Cardiovascular Therapy Area and Head of Medical Research, in the 20 years he has been with the company. He is a Fellow and past Board member of the Faculty of Pharmaceutical Medicine. |
Contact details
Granta Park
Cambridge
CB1 6GH, UK
Tel: +44 (0) 1223 471471
